Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab

The purpose of this study is to evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure variations after intravitreal bevacizumab injection.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age Related Macular Degeneration Cardiovascular Diseases Diabetes Complications Diabetes Mellitus Diabetic Angiopathies Diabetic Retinopathy Endocrine System Diseases Eye Diseases Macular Degeneration Retinal Degeneration Retinal Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of age related macular disease or diabetic retinopathy
Able and willing to provide informed consent

Exclusion criteria

History of ocular hypertension or glaucoma
High Myopes (> 6 spherical diopters)
High Hyperopes (> 4 spherical diopters)
Pulmonary disease
Renal disease
Known allergy to any component of the study drug
Myocardial infarction, transient ischemic attack within 4 months prior to randomization or any contraindication for bevacizumab use

Treatment and study plan

Acetazolamide

Drug

250 mg 1 hour before intravitreal injection

Other names: Diamox

Brimonidine tartarate

Drug

1 drop 1 hour before intravitreal injection

Other names: Alphagan

anterior chamber paracentesis

Procedure

Immediately after bevacizumab injection

Primary outcomes

Intraocular pressure (mmHg)

Time frame: 1 hour and, 3 minutes before IVI. 3,10,20, 30 minutes after IVI

Sponsors and collaborators

Lead sponsor

University of Sao Paulo

Other

Collaborators

Fundação de Apoio ao Ensino Pesquisa e Assitência do HCFMRPUSP

Registry information

Official study title

Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Injection

Important dates

Study start: 2008
Primary completion: 2009
Study completion: 2009
First posted: Mar 19, 2009
Registry last updated: Mar 19, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed